Alvogen to buy four pharmaceutical products from Pfizer for US market
In the US market, Alvogen has a pipeline of more than 60 ANDA’s, of which 28 have first-to-file or first-to-market potential. The deal will further diversify and strengthen
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and bupropion HCl) to treat agitation associated with dementia due to Alzheimer’s.
Immatics believes that ACT approaches to be developed by the new company can achieve a step change in the treatment of cancer, by delivering significant, long-lasting clinical benefits.
The AMBITION study was a randomised, double-blind Phase 3b/4 study designed to compare the efficacy and safety of ambrisentan in combination with tadalafil to monotherapy in treatment-naïve patients
The product, which is based on Corium’s proprietary transdermal formulation and adhesive technology, is designed to deliver donepezil (the active ingredient in Aricept) for up to seven days